Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics Portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.


News

Gosia Trynka awarded 2020 Leena Peltonen Prize

Saturday 6 June 2020 | Cambridge, UK

Open Targets is excited to announce that Gosia Trynka, our Experimental Science Director, has been awarded the 2020 Leena Peltonen prize by the European Society for Human Genetics (ESHG).

The prize is given every two years to an outstanding young researcher in the field of human genetics and it honours the memory of Dr. Leena Peltonen, a world-renowned human geneticist from Finland who contributed greatly to the identification of disease genes for human diseases.

Alongside her work as a member of the Open Targets Executive Leadership Team, Gosia has been leading the Immune Genomics Group at the Wellcome Sanger Institute since 2014. Her group combines immunology and genomic assays with statistical approaches to study how human genetic variation impacts the immune system and predisposes to the development of autoimmune diseases.


Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collabortive projects that improve how we systematically identify and prioritise drug targets.


Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Rapid publication

We are committed to rapid publication and making data, methods and results publicly available as soon as possible

Open collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data


Follow Us


Open Targets Platform 20.06 has been released!

Denise Carvalho-Silva | June 17, 2020

We have a new release of the Open Targets Platform: new disease terms including COVID-19, new che...

Open Targets Platform: adding FDA data with Scala and Spark

Jarrod Baker | June 05, 2020

Leveraging Spark and Scala to implement a performant ELT pipeline to integrate the FDA Adverse Ev...

Open Targets Platform 20.04 has been released!

Denise Carvalho-Silva | April 27, 2020

We have a new release of the Open Targets Platform with new target safety data, new target tracta...

Prioritising your list of potential drug targets with tractability assessments

Melanie Schneider | April 23, 2020

How tractable is a drug target? In this Open Targets Q&A, we explore the ChEMBL tractability (dru...

GWAS causal inference in Open Targets

David Ochoa | April 07, 2020

Finding GWAS causal inference for target identification and prioritisation using Open Targets Gen...